Consideration of Pneumonectomy in the Era of Chemo-Immunotherapy in Resectable NSCLC

Introduction Recently, there has been increasing evidence for the use of neo-adjuvant chemoimmunotherapy in patients with resectable lung cancer. We aimed to analyze the pneumonectomy rates in the recently published phase 3 trials (including CM 816, KN 671, AEGEAN, and NEO-TORCH)[ 1 ] [ 2 ] [ 3 ] [ 4 ] in patients with resectable NSCLC and compare them with historical data. In this paper, we highlight the changing total surgical and pneumonectomy rates in the era of chemo-immunotherapy in resectable nonsmall cell lung cancer (NSCLC) patients. Ethical Approval The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Publication of this editorial and accompanying figures was waived from patient consent according to the UCI ethics committee/institutional review board. Publication History Received: 24 January 2025 Accepted: 18 March 2025 Article published online: 21 April 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany